How to Buy Grifols Sa Stock
Grifols Sa
Grifols, S. A. , a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma.
Grifols Sa stock last closed at $7.40, down 0.8% from the previous day, and has decreased 14.94% in one year. It has underperformed other stocks in the Drug Manufacturers - General industry by 0.46 percentage points. Grifols Sa stock is currently +1.93% from its 52-week low of $7.26, and -33.57% from its 52-week high of $11.14.
There are currently 687.55M GRFS shares outstanding. The market capitalization of GRFS is $5.09B. In the past 24 hours, 1.03M GRFS shares were traded.
How to Buy Grifols Sa Stock
Not sure how to invest in Grifols Sa stock? Here's how.
- Figure out where to buy Grifols Sa stock: You need to choose an online brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you decide where to buy Grifols Sa stock.
- Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Fund your investment account: Select your payment method and add your information.
- Research Grifols Sa stock: The Grifols Sa ticker symbol is GRFS. Is Grifols Sa stock a good investment? Should you buy shares of GRFS? How do GRFS's underlying business fundamentals look? Do top analysts think Grifols Sa is a good buy? Why has GRFS's stock price moved recently? (Hint: Our stock research tools can help you figure out if GRFS is a good stock to buy).
- Execute your GRFS trade: Decide if you will purchase GRFS shares at the current market price or use a limit order to purchase GRFS shares at a specific price.
- Get the latest scoop on your investment in GRFS: Create a watchlist to watch your new investment in Grifols Sa shares.
Step 1: Figure out where to buy Grifols Sa stock
You will need an online brokerage account to access the NASDAQ market and buy GRFS stock.
Our preferred brokerage: eToro
In our opinion, eToro is the best stock brokerage. Here's why:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world markets: From Technology to Financial Services, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading stock exchanges.
- Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've selected the right brokerage, the next step is to fill out some personal details so you can buy GRFS stock today.
How to Set Up a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal details to start your new trading account.
- Send your details by pressing the "Create Account" button. Get started with eToro today
Step 3: Fund your investment account
Now that you have finished signing up on app for stock, your next step is to transfer the money for your investment:
Watch the video below to see the process of transferring funds into your new investment account.
Step 4: Research Grifols Sa stock
Once you have chosen the best place to buy Grifols Sa stock, it's very important to analyze their stock before you buy, so you actually wrap your head around the risk and opportunity.
Grifols Sa Numbers
Grifols Sa Due Diligence Score
WallStreetZen was created to help everyday investors do better fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on GRFS's stock page.
What is the fair value of GRFS stock?
Analysts use many financial metrics, analyses, models, and charts to gauge GRFS's intrinsic value.
Using relative valuations metrics:
- GRFS could be undervalued based on its P/E ratio of 10.79x, relative to Drug Manufacturers - General industry P/E ratio of 36.29x
- GRFS may be undervalued based on its P/B ratio of 0.83x, relative to Drug Manufacturers - General industry P/B ratio of 7.04x
- GRFS could be undervalued based on its PEG ratio of 0.41x
You can do additional valuation analysis on GRFS's stock here.
GRFS Financials at a glance
Positive Health Checks:
- GRFS profit margin has gone up from 2.2% to 5.3% in the past year.
- There are more short-term assets than short-term liabilities on the GRFS balance sheet.
Negative Health Checks:
- GRFS earnings of $1.33B is not sufficient to cover its interest payments.
- GRFS has a relatively high debt to equity ratio of 2.3.
- Total GRFS debt is higher than 5 years ago, relative to shareholder equity.
- GRFS's operating cash flow of $1.22B allows it to safely service it's debt of $11.21B.
- There are more long-term liabilities than short-term assets on the GRFS balance sheet.
You can dig deeper into what analysts are forecasting on the Grifols Sa stock forecast page.
GRFS Trading Indicators
How are GRFS Revenues/Earnings doing?
Last year, GRFS earnings were $467.44M. Over the past 5 year, GRFS's earnings have gone up by -8.77% per year. This was slower than the Drug Manufacturers - General industry average of 16.77%.
Last year, GRFS revenue was $8.75B. During the last 5 year, GRFS's revenue has gone up by 6.33% per year. This was slower than the Drug Manufacturers - General industry average of 10.84%.
You can research GRFS's earnings and revenue performance here.
Are GRFS executives and large shareholders buying or selling the stock?
Over the last 12 months, insiders at GRFS have not bought or sold any shares.
Research more about who owns GRFS shares here.
Does GRFS provide a stable income stream?
Grifols Sa pays a dividend of 2.34%, compared to the Drug Manufacturers - General industry's average dividend yield of 2.81%. If you owned $1,000 worth of GRFS stock, you would have received $23.43 in the past year.
Grifols Sa dividend payments have consistently grown over the past decade but have not remained stable.
Find more analysis about Grifols Sa dividend yield and history here.
What do other investors have to say about GRFS?
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Execute your GRFS trade
There are two primary types of orders:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are generally sufficient. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to ensure you're buying or selling at a given price limit, use a limit order.
Press the Open button and eToro will execute your order.
If you need additional assistance investing in stocks on eToro, click the helpful video below:
Step 6: Get the latest scoop on your investment in GRFS
Now that you own some GRFS shares, you'll want to keep up with your shares.
Create a watchlist to get notified of the latest news about your GRFS stock.
GRFS Feed
How to Buy Stock in Grifols Sa
To summarize, here are the 6 steps to buy Grifols Sa stock:
- Figure out where to buy Grifols Sa stock
- Create your brokerage account
- Fund your investment account
- Research Grifols Sa stock
- Execute your GRFS trade
- Get the latest scoop on your investment in GRFS
If you need a brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you would like to watch your new investment in Grifols Sa, add GRFS to your watchlist by clicking the button below.
Trending "How To" Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.